Nasdaq: SNGX
Download the recent Soligenix CEO Q&A on Positive Phase 3 CTCL Data and The Covid 19 Program
Soligenix is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures on our website www.pcgadvisory.com.
© Soligenix, 2020. All Rights Reserved.
Soligenix is a late-stage biopharmaceutical company that seeks to fulfill unmet needs in the medical field by developing and commercializing products to treat rare diseases. The company has two distinct business segments: Specialized BioTherapeutics, focusing on oncology and inflammation, and Public Health Solutions, focusing on federally funded vaccine developments.
Together, these two business arms create an environment ripe for opportunity with major milestones expected in the coming months.
Soligenix is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures on our website www.pcgadvisory.com.
Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma
LATEST UPDATE